** Shares of drugmaker SpringWorks Therapeutics SWTX.O rise 10.12% to $61.37 premarket
** Co says it will not host a conference call to discuss its quarterly earnings, which Evercore ISI analysts say confirms that its negotiations with Germany's Merck KGaA MRCG.DE for a potential buyout "are still very much alive"
** Reuters reported on February 10 that Germany's Merck KGaA MRCG.DE was in advanced talks to acquire the company; Merck subsequently confirmed the talks
** Separately, SpringWorks posts Q4 revenue of $61.5 mln, versus analysts' est of $59.1 mln, as per data compiled by LSEG
** "This morning's 4Q print is in-line (recall January pre-announcement) and irrelevant," says Evercore ISI
** Stock has risen 3.2% since the Reuters report and 13.5% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。